DMPK科学在提高药物研发效率中的作用,Drug Discovery Today

药物开发管道中候选药物的成功监管机构批准率对于确定药物研发 (R&D) 效率至关重要。监管机构包括美国食品和药物管理局 (FDA)、欧洲药品管理局 (EMA) 和日本药品和食品安全局 (PFSB) 等。最佳药物代谢和药代动力学 (DMPK) 特性影响候选药物从临床前阶段到临床阶段的进展。在这篇综述中，我们对 DMPK 科学的基本概念、方法、改进和挑战及其在药物开发中的意义进行了全面评估。该信息提供了对 DMPK 科学与药物研发效率之间关联的见解。

"点击查看英文标题和摘要"

The successful regulatory authority approval rate of drug candidates in the drug development pipeline is crucial for determining pharmaceutical research and development (R&D) efficiency. Regulatory authorities include the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and Pharmaceutical and Food Safety Bureau Japan (PFSB), among others. Optimal drug metabolism and pharmacokinetics (DMPK) properties influence the progression of a drug candidate from the preclinical to the clinical phase. In this review, we provide a comprehensive assessment of essential concepts, methods, improvements, and challenges in DMPK science and its significance in drug development. This information provides insights into the association of DMPK science with pharmaceutical R&D efficiency.